Terazosin treatment in BPH/LUTS: a prospective, randomized, multicenter study
10.3760/cma.j.issn.1000-6702.2011.03.021
- VernacularTitle:特拉唑嗪治疗良性前列腺增生及下尿路症状有效性和安全性的前瞻性多中心研究
- Author:
Xiang WANG
;
Zhong CHEN
;
Mujun LU
;
Yuan SHAO
- Publication Type:Journal Article
- Keywords:
Prostatic hyperplasia;
Terazosin;
Lower urinary tract symptoms;
Qmax
- From:
Chinese Journal of Urology
2011;32(3):206-208
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and safety of 2 mg/d and 4 mg/d of terazosin in the treatment of benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS).Methods A total of 120 BPH patients were randomly divided into 2 groups receiving 2 mg or 4 mg terazosin per day for 2 months. Arterial blood pressure, International Prostatic Symptom Score (IPSS) and peak flow rate (Qmax) before and after treatment were compared while side effects were estimated. Results Forty-six patients receiving 2 mg and 54 patients receiving 4 mg terazosin completed this study. Patients' age and pre-treatment blood pressure, IPSS and Qmax had no difference between the 2 groups. The improvement of IPSS (including obstructive score, irritating score and total IPSS) and Qmax was significantly better in 4 mg group. The percentage of patients experiencing greater than 30% improvement in Qmax in the 4 mg treatment groups was significantly higher than that of the 2 mg group (46.3% vs 23.9%, P=0.02). Side effects were rare and mild in both groups.Conclusion The improvements of IPSS and Qmax are significantly greater in 4 mg treatment of terazosin than that of 2 mg with no obvious increase of side effects.